Biphasic insulin aspart in the treatment of type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy
Domenico Cucinotta, Giuseppina T Russo

Abstract

Initiating and implementing insulin treatment in type 2 diabetic subjects is a major challenge in diabetes clinical practice. Although simple regimens, such as the combination of a once-daily basal insulin + oral agents, are widely used, they often are not able to achieve an adequate glycemic control, especially in the postprandial period. Biphasic insulin analogues are a valid tool to start and to improve insulin treatment in type 2 diabetes. Biphasic insulin aspart (BIAsp) is available in three different mixtures (30, 50 and 70% of rapid-acting insulin, respectively), which allows insulin treatment to be individualized. To review recent published papers concerning pharmacological properties and clinical use of BIAsp in type 2 diabetes. BIAsp seems to have some advantages over biphasic human insulins, especially for its practical pre- or post-meal administration and lesser hypoglycemic risk. Against basal insulins once daily, BIAsp twice daily seems to perform better in achieving the glucose targets and, even when compared with the more complex basal-bolus regimens, a BIAsp-based treatment using the different available mixtures is at least non-inferior. Side effects are no more frequent than with other insulins; more hypoglyce...Continue Reading

References

Jun 1, 1990·Diabetes Care·M C Riddle
Jun 6, 2000·Advanced Drug Delivery Reviews·J Brange, A Vølund
Sep 29, 2000·European Journal of Clinical Pharmacology·L V JacobsenA Riis
Dec 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·P D HomeUNKNOWN European Insulin Aspart Study Group
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group
Mar 8, 2006·Clinical Therapeutics·Jaime DavidsonRyuzo Kawamori
Nov 23, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·R J LigthelmA Liebl
Nov 23, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·P H KannM Regulski
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Jul 20, 2007·Annals of Internal Medicine·Shari BolenFrederick L Brancati
Jan 10, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Jan 30, 2009·Basic & Clinical Pharmacology & Toxicology·Rannveig Linda ThorisdottirJens Sandahl Christiansen

❮ Previous
Next ❯

Citations

Oct 16, 2010·Advances in Therapy·Walid K H FakhouryTorsten E Christensen
Dec 2, 2010·The Annals of Pharmacotherapy·Henry A SpillerBrooke L Wilson
Nov 28, 2017·Current Medical Research and Opinion·Chaicharn DeerochanawongUnchalee Permsuwan
Jan 4, 2017·International Journal of Endocrinology·Giuseppina T RussoDomenico Cucinotta
Jan 1, 2015·Expert Review of Endocrinology & Metabolism·Awadhesh Kumar Singh
Jul 1, 2010·Expert Review of Endocrinology & Metabolism·Ryuzo Kawamori, Paul Valensi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.